The response rate and safety profile of T315I patients were comparable to those observed in the overall population of refractory CML and Ph+, ALL patients in ponatinib clinical trials.8 No mutation conferring resistance to Ponatinib, so far, has been identified.2,9,10 With longer follow-up and the availability of second and third generation TKIs, most clinically relevant ABL kinase mutations respond to change in TKI therapy following imatinib failure, with the majority of patients achieving durable cytogenetic and molecular responses. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.